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An intricate link exists between the neuroendocrine and immune systems; how-
ever, the mechanisms responsible for thislinkage are not understood. a-Endorphin
(O-END)' and the related pentapeptides methionine-enkephalin (METENK) and
leucine-enkephalin (LEU-ENK) belong tothe opioid family ofneurohormones, which
were originally identified in brain tissues for theiranalgesic effects but are now rec-
ognizedto have activity in theperiphery, aswellasthe centralnervous system (CNS)
(1-3). Endogenous secretion of these neuropeptides correlates with autonomous
rhythms, physical activities, and emotional states (2, 4). Circulatinglevels ofa-END
are increased with certain kinds of stress, and although speculative, it is possible
that thestress-induced release ofthis orotheropioids is relatedtothe abilityofstress
to alter lymphocyte function (2, 4).
Evidence from both invivo pharmacological andin vitro biochemical studies sug-
gests that opioids bind to opiate/opioid receptors and that such receptors exist in
multiple forms (1, 5). Opioid bindingsites have been best describedfor nervous tissues
prepared from rodents or other animals and for cultured neuroblastoma or neuro-
blastoma-hybrid cells (1, 2, 5-7). Radiolabeled ligands and synthetic peptides with
high affinity for specific types of receptors have been used to characterize opioid
binding sites (1, 5). It isgenerally accepted thata-END, METENK, or LEU-ENK
bind to opiate%pioid receptors of the 6 and j types (1, 2, 5). Analgesic activity of
these neuropeptides resides in their common NH2-terminal amino acid sequences
(HTyr-Gly-Gly-Phe-Met-OH or -Leu-OH) and is reversed by opiate receptor an-
tagonists such as naloxone (1, 2). Opioids also bind to other (nonclassical) sites and
such binding, unlike that tothe opiate%pioid receptors, is naloxone irreversible and
not strictly dependent on the NH2 terminus of the peptides (1-3).
The first evidence that indicatedthat opioids exertedeffects on the immunesystem
was the observation in 1979 by Wybran et al. (8) that rosetting between human T
cells and sheep erythrocytes was increased by METENK. Since then there have
been conflicting reports concerning the effects ofopioids on lymphocytes (2, 3) and
the significance ofthese peptides in relation to lymphocyte function has remained
a matter for speculation (2, 3). Some investigatorshave reportedthat lectin-induced
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proliferation and lymphokine secretion were enhanced by /3-END whereas others
have found this opioid inhibitory (reviewed in references 2 and 3). Lymphocyte re-
sponsiveness to mitogens including blastogenesis and release of lymphokines must,
by necessity, be measured in the presence ofaccessory cells(9). The previous studies
(2, 3) have relied on mixed populations (i.e., cultures of PBMC, which may ac-
count, at least in part, for the difficulty in clearly defining the effects of opioids on
lymphocyte function. There is also confusion in the literature concerning the mech-
anism(s) by which opioids act on immune cells(3) . The effects of O-END on prolifer-
ation and lymphokine secretion have been ascribed to naloxone irreversible (non-
opiate receptor) mechanisms; however, the enhancement of T cell rosetting caused
by METENK was abolished by this opiate receptor antagonist (reviewed in refer-
ences 2-4).
To gain a better understanding of the actions of opioids on immune function we
chose to focus on T lymphocytes because these cells are crucial for both cellular and
humoral immunity (10). Previously, a-END and other opioids have been shown to
affect the motility of leukocytes derived from myeloid precursors (11-14). We have
used a cell migration assay to measure the effects of endogenous and synthetic opioids
on highly purified human peripheral blood T cells. Since migration is a lymphocyte
behavior mediated by direct interaction of soluble factors with cell surface receptors
(15), these assays allowed us to characterize the opioid binding sites on T cells and
compare our findings with known propertiesof the opiate/opioid receptors on nerve
cells. In this communication we show that T cell migration is affected by direct in-
teraction with physiological concentrations of a-END or the enkephalins. Synthetic
peptides with a high degree of specificity for classical S or h opiate/opioid receptors
were, like the endogenous opioids, stimulatory. Moreover, activity was dependent
on the integrity of the opioid NH2 terminus and inhibited by naloxone. We pro-
pose that human peripheral blood T cells have opiate/opioid receptors analogous
to the S and Ft types previously described for neurons (1, 5) and that endogenous
opioids may be signaling agents that play a significant role in directing T cell
movement.
Materials and Methods
Preparation ofHuman PeripheralBlood T Cells.
￿
T lymphocytes were prepared from buffy coats
(American Red Cross, Boston, MA) by a three-step protocol. First, human PBMC were pre-
pared on a Ficoll-Hypaque gradient. The PBMC were then passaged over nylon wool to elim-
inate B cells and macrophages. In the third step, CD16' (natural killer) cells were coated
with a saturating amount of B73.1 (mouse anti-human CD16 mAb) (16) and then absorbed
on goat anti-mouse coated beads (BioMag beads; Advanced Magnetics, Inc., Cambridge,
MA). Cells recovered in a typical preparation were >,97% CD3' as assessed by flow cy-
tometry.
Opioids and Synthetic Peptides.
￿
The preparations of purified human S-END used in these
studies were from Calbiochem-Behring Corp. (LaJolla, CA). The naturally occurring pen-
tapeptides LEU-ENK (Tyr-Gly-Gly-Phe-Leu) and METENK (Tyr-Gly-Gly-Phe-Met), and
the synthetic peptides [u-Ala-2,N-Me-Phe'Met(o)4-of]-enkephalin (FK 33-824), (D-Ala2, o-
Leu']-enkephalin (DADLE), (D-AW,Me-Phe', Gly(ol)']-enkephalin (DAGO), [D-Ser2Leu']-
enkephalin Thb (DSLET), cyclic [p-Pen2,n-Pen']-enkephalin (DPDPE), and H-Gly-Gly-Phe-
Leu-OH (DesTyr-LEU-ENK) were purchased from Sigma Chemical Co. (St. Louis, MO).
Naloxone (Narcan) was obtained from Dupont Pharmaceuticals (Manati, Puerto Rico).
Migration Assays.
￿
A microchemotaxis chamber (Neuroprobe, Inc., CabinJohn, MD) wasHEAGY ET AL.
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used to measure T cell migration. Lymphocytes (5 x 106/ml) within the upper reservoirs
were separated from peptides in the lower wells by a nitrocellular filter (Sartorious, 8 /m
pore; Neuroprobe, Inc.) and were incubated for 1.5 h at 37°C. The filter was then fixed,
stained with Congo red dye (Sigma Chemical Co.), and mounted between glass slides, as
previously described (17). Cells which migrated into the filter were identifiedby fluorescence
microscopyand then enumerated using-an optical image analyzer (Optomax V image analyzing
system; Analytical Instruments, Hollis, NH).
Statistical Analysis.
￿
Data analyses were performed on the PROPHET system, a national
computer system sponsored by the Chemical/Biological Information Handling Program, Na-
tional Institutes of Health, Bethesda, MD. Values measured for stimulated and control cells
(spontaneous locomotion) were compared for each distance measured through the filter. The
effects of the opioids on T cell migration were evaluated by using appropriate comparison
procedures (paired t-test or Dunnet's test).
Results
Endogenous Opioids Are Chemotacticfor Human T Cells.
￿
Endogenous opioids were
potent stimulators of human T cell migration (Figs. 1-3). The response measured
for /3-END, LEU-ENK, and METENK was greater (p <0.001; paired Mest; p <
0.01, Dunnett's test) than the spontaneous locomotion (i .e., response measured for
assay buffer alone) (Figs. 1-3). The effect exerted by the opioids was dose depen-
dent, peaking at 10-5 M; the half-maximal response was measured at dilutions of
10 -1° M and the activity titered to opioid doses as low as 10 -'3 M (Fig. 1 B).
T cell migration may, in theory, result from an enhancement in random motion
(chemokinesis) or directed movement in response to a concentration gradient
(chemotaxis) (15). To distinguish between these two types of locomotion we carried
out experiments where in some test wells the stimulus was added in equal concentra-
tions to both the upper and lower chambers, thereby abolishing the concentration
gradient between the wells. By comparing the responses measured in the presence
or absence of the gradient we were able to distinguish between chemotaxis and
chemokinesis. When (3-END was added to only the lower wells, and thus a gradient
existed between the upper and lowerchambers, T cellsmoved into the filters (p <0.001;
paired t-test; p <0.01 ; Dunnetts test) (Fig. 2). The response, on the other hand, was
equivalent to the spontaneous locomotion (p >0.05, NS; paired t-test) when /3-END
was added to both upper and lower chambers (i.e., in the absence of a gradient).
These findings indicate that T cell migration to /3-END is dependent upon a con-
centration gradient between the upper and lower chambers, and therefore, the ac-
tivity is chemotactic.
When T cells were challenged with METENK or LEU-ENK at doses between
10-13 and 10-9 M, migration was measured only when a gradient existed between
the upper and lower wells, and therefore, the activity was chemotactic. At very high
concentrations (10-7 to 10-5 M) locomotion was measured in the presence or ab-
sence of a gradient; therefore, at nonphysiological concentrations (10-7 to 10-5 M)
enkephalins stimulate chemokinesis.
Naloxone BlockedTCell Locomotion to Opioids.
￿
T cell migration in response to MET
ENK or LEU-ENK was inhibited by naloxone (Table 1). As expected, this opiate
receptor antagonist had no effect on locomotion caused by the lymphokine IL-2;
the response to IL-2 was equivalent for naloxone-treated or nontreated cells (with
or without Naloxone; Table 1), indicatingthat naloxone was not nonspecifically toxic
for the lymphocytes.1628
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Fic .URE 1 . Human peripheral blood T lymphocytes migrate to S-endorphin and leucine-
enkephalin . /3-END and LEU-ENK were prepared in Dulbecco's modified PBS with 0.1% chick
eggalbumin (assay buffer)and then added in 35 Al volumes to the lower wells ofthe chemotaxis
chamber . A nitrocellulose filter was placed between the upper andlower reservoirs of the cham-
ber and the lymphocytes (5 x 10 6/ml) were then added to the upper wells in 60-Al portions of
assay buffer. After a 1.5-h incubation at 37°C the filters were removed, fixed, and stained with
Congo red dye (13). Migration was scored for triplicate wells utilizing an opticalimage analyzer ;
10 high power fields (hpf) were measured at 10 Am distances through the filter. Data are pre-
sented as the means f SD for 30 values (i .e ., 10 readings x triplicate assays) . (A) /3-END and
LEU-ENK were added to the lower reservoirs as 10-9M solutions . (B) LEU-ENK was added
to the lower wells at the dilutions indicated. Migrationwas scored as described forA . Total counts
were determined by adding the values measured at 10Am intervals through the filter . The data
are presented as the Migration Index (the number of cells measured forLEU-ENK/thenumber
measured for the spontaneous locomotion) .
Enkephalin Analogues with Specificityfor,uorb ReceptorsEnhancedTCell Locomotion.
￿
Syn-
thetic peptides that bind to u or 6, or both types, of opiate/opioid receptors stimu-
latedT cell migration, albeit, to alesser extent than the endogenous opioids MET
ENKor LEU-ENK (Fig . 3, A-C) . The responsemeasured for.enkephalin analogues
including : FK 33-824, DSLET, DPDPE, DADLE, or DAGO wasgreater then spon-
taneous locomotion (p <0.01, Dunnetts test). It is noteworthy that the response was
enhanced by theanalogueDAGO (Fig . 3 C) in as much as this peptide shows specificity
for the t. type opioid/opiate receptor (1, 5, 18, 19) . Peptides with high affinity for
S receptors were also stimulatory as indicated by the fact that DPDPE or DADLE
were stimulatory (p <0 .01; Dunnetts test)) (Fig . 3, B and C) (1) .
To further characterize theT cell sites we measured the response to anonanalge-
sic peptide, DesTyr-LEU-ENK which is identical to LEU-ENK except that the
NH2-terminal tyrosyl of the opioid is absent from this analogue (20, 21) . Whereas
LEU-ENK was stimulatory, DesTyr-LEU-ENK had no effect onT cell migration
(p >0.05) (Fig . 3 A), indicating that the NH2 terminus of the peptides must be crit-
ical to their activity.HEAGY ET AL .
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FIGURE 2 .
￿
/3-endorphin stimulates humanT cell chemotaxis . Assays to distinguish chemotaxis
andchemokinesiswere as described for Fig . 1 except that preparations ofS-ENDwere dispensed
to the lower [(-)/(+)] or the upper and lower [(+)/(+)] wells as indicated. The data of Fig . 2
were obtained by measuring the response ofT cells from a single donor to S-END : (A) 10-9
M ; (B) 10-7 M; and (C) 10-5 M . Migration was measured as described for Fig. 1 A.
Discussion
Our studies show that the naturally occurring opioids O-END, METENK, or
LEU-ENK and enkephalin analogue with a high degree of specificity for classical
6 or IA opiate/opioid receptors caused an enhancement in the directed locomotion
ofhuman peripheral blood T cells . This response was dependent on the integrity
of the opioid NH2 terminus (Fig . 3 A) and inhibited by naloxone (Table 1) . Previ-
ously, [3H]naloxone (22) and a synthetic ligand specific for the 6 receptors (23) have
been shown to bind to T cells ; however, the physiological significance of these
opiate/opioid binding sites was unclear . Our studies indicate that T cell function
is affected by direct interaction with opioids and that these cells have classical J,,
as well as 6 type opiate/opioid receptors .
In our assays a greater number of cells responded to METENK or LEU-ENK
than to their analogues (Fig . 3) . The synthetic peptides, on theotherhand, are more
potent analgesics thanMETENK or LEU-ENK (1). Endogenous opioid pentapep-
tides are rapidly hydrolyzed in vivo by aminopeptidases (1, 20, 21); however, their
analogs are more resistant to such enzymatic activity (1, 20, 21) . Possibly, the level
of degradation in our in vitro assays is less than that in vivo and differencesbetween
the rates at which the natural pentapeptides are inactivated may account, at least
partially, for this apparent dissimilarity.
Tlymphocytes are highly motileimmune response cells whichprobably accumu-
late in inflammatory sites by recruitment from the blood (15, 24) . Evidence from163 0 NEUROHORMONES REGULATE T CELL FUNCTION
TABLE I
Naloxone Inhibits T Cell Migration to Methionine-Enkephalin and Leucine-Enkephalin
T cells (prepared as described in Materials and Methods) were cultured in RPMI 1640 medium supplemented
with 2 % FCS, 100 U/ml ofpenicillin'/streptomycin and 2 mM glutamine, or in the culture medium con-
taining 10-5 M naloxone for 15 h at 37°C in a 5% C02 atmosphere. Viability of the cells incubated with
or without naloxone was equivalent (->97%), as judged from vital staining with trypan blue. Lymphocytes
pretreated with naloxone were added to the upper wells of the migration chamber in assay buffer (Dulbec-
co's modified PBS with 0.1% chick egg albumin that contained naloxone (10-5 M).
$ The data were obtained in two experiments with lymphocytes from different donors.
s Migration was scored as described for Fig. 1 A . Total counts were obtained by adding the values mea-
sured at 10-,um intervals through the filter.
~~ Specific migration was determined by subtracting the spontaneous response to assay buffer (spontaneous
locomotion) from the stimulated responses .
The effect of naloxone on specific migration is shown as percent response = [specific migration for cells
treated with naloxone/specific migration for nontreated cells] x 100% .
in vitro studies suggests that cytokines released by immune cells play a role in recruit-
ment (15, 24). Murine T helper lines have been shown to secrete enkephalins and
enkephalin-related peptides (10, 25) and human P13MC have been reported to re-
lease endorphins (4). Our studies show the opioids to be potent T cell chemoattrac-
tants (Figs. 1 and 2). Possibly, local release of opioids may stimulate T cell move-
ment from the blood to immune response sites.
Under normal, nonstressful conditions circulating levels of /3-END are between
1 and 100 x 10-12 M (26-28). The basal level is increased 3-10-fold with exercise
(28), certain kinds of stress (29), and during pregnancy, labor and delivery (30).
Studies carried out in animal models have shown that the levels of a-END within
the brain may be as much as 100 times that in the periphery (31). Physiological con-
centrations of (3-END and other opioids have been reported to have effects on the
motility of phagocytes including human neutrophils and monocytes (11-14). Our
studies show opioids stimulate T cell chemotaxis at concentrations detectable in pe-
ripheral blood (Figs. 1-2). Taken together these studies suggest that opioids have
potent effects on the motility of immune response cells. Within the body immune
cells move in and out of the blood and the circulating level of opioids may control
both entry and exiting of such cells. Interestingly, Stefano et al. (32) have shown
that opioids affect the motility ofimmunocytes (amebocytes) harvested from animals
Donorl Stimulus
Without
Total
counts
Treatments'
naloxone With
Specific Total
migration1l count
naloxone
Specific
migration
Effect of naloxone
on specific migrations
(percent response)
4 MET-ENK (10- " M) 1,460 830 582 2 0.2
MET-ENK (10-9 M) 3,250 2,620 915 335 12.8
IL-2 (100 U/ml) 2,070 1,440 2,048 1,468 102.0
Assay Buffer (Spontaneous
locomotion) 630 0 580 0
5 MET-ENK (10-5 M) 4,998 3,093 2,550 768 24.8
LEU-ENK (10-5 M) 5,076 3,171 2,364 582 18.4
Assay Buffer (Spontaneous
locomotion) 1,905 0 1,782 0HEAGY ET AL.
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FIGURE 3 .
￿
Synthetic enkephalin analogs selective for p or S opioid/opiate receptors stimulate
T lymphocyte migration . Assays were as described for Fig . 1 A except that the peptides were
diluted to 10 -5M in assay buffer and then added to the lower wells of the chemotaxis chamber.
Data are presented as for Fig. 1 A. (A) FK 33-824, [n-Ala-2,N-Me-Phe4Met(o)4-01]-enkephalin ;
Des-Tyr-LEU-ENK, ~H-Gly-Gly-Phe-Leu-OH) . (B) DSLET, [o-Ser2Leu'l-enkephalinTh 6;
DPDPE, cyclic (n-Pen ,p-Pen sl-enkephalin . (C)DADLE, [o-ala2,o-Leull-enkephalin ; DSLET,
[o-Ser2Leu I-enkephalinTh6 ; DAGO, [o-Ala2 ,MePhe 4,Gly(ol)'j-enkephalin . (A, B, and C) Three
different experiments performed with cells from three different donors .
belonging to twophyla of invertebrates, themollusc Mytilis edulis and the insect Leu-
cophaea maderae . The studies by Stefano and coworkers show that opioid effects are
not restricted to mammals and suggest that opiate/opioid receptors developed early
in the course of evolution (32) . To date, no other cytokines or microbial products
have been shown to affect the locomotion of such diverse kinds of immune cells .
Our studies show that opioids affect humanT cell movement and sinceT cells are
crucial for cellular and humoral immunity our findings provideevidence that these
neurohormones are immunoregulatory agents which probably exert significant control
on immune function .
Summary
In this communication we show that T cell locomotion is affected by direct inter-
action with neurohormones . Opioid peptides, including/3-END, METENK, LEU-
ENK, and related enkephalin analogues enhanced migration ofhuman peripheral
bloodT lymphocytes . Activity was dependent on the peptide NH2-terminal se-
quence, stimulated by enkephalin analogues with specificity for classical 6 or u types
of opiate receptor, and inhibited by the opiate receptor antagonist naloxone . Our
studies suggest that such neuropeptides stimulateT cell chemotaxis by interaction
with sites analogous to classical opiate receptors . We propose that the endogenous1632
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opioids /3-END, METENK, and LEU-ENK are potent immunomodulating signals
that regulate the trafficking of immune response cells.
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